Viking Therapeutics Retained Earnings (Accumulated Deficit) 2014-2024 | VKTX
Viking Therapeutics retained earnings (accumulated deficit) for the quarter ending June 30, 2024 were $-0.428B, a 29.25% increase year-over-year.
- Viking Therapeutics retained earnings (accumulated deficit) for 2023 were $-0.378B, a 29.41% increase from 2022.
- Viking Therapeutics retained earnings (accumulated deficit) for 2022 were $-0.292B, a 30.86% increase from 2021.
- Viking Therapeutics retained earnings (accumulated deficit) for 2021 were $-0.223B, a 32.69% increase from 2020.